Table 1 Correlation of PRICKLE1 expression with clinical and laboratorial parameters in AML patients
Patient's parameters | Total (n = 129) | Status of PRICKLE1 expression | P value | |
|---|---|---|---|---|
High (n = 65) | Low (n = 64) | |||
Sex, male/female | 77/52 | 35/30 | 42/22 | 0.236 |
Median age, years (range) | 51 (12–81) | 52 (14–81) | 50(12–80) | 0.421 |
Median WBC, × 109/L (range) | 15.60(0.30–381.60) | 19.90 (0.30–381.60) | 13.31 (0.65–263.45) | 0.260 |
Median hemoglobin, g/L (range) | 73 (33–151) | 73 (33–141) | 75 (36–151) | 0.642 |
Median platelets, × 109/L (range) | 30 (2–984) | 32 (2–277) | 27 (5–984) | 0.456 |
Median BM blasts %, (range) | 73.0 (16.0–97.0) | 78.0 (16.0–97.0) | 66.0 (21.0–97.0) | 0.036 |
FAB subtypes (%) | < 0.001 | |||
M0 | 1 (0.8) | 0 (0.0) | 1 (1.6) | |
M1 | 13 (10.1) | 6 (9.2) | 7 (10.9) | |
M2 | 49 (38.0) | 13 (20.0) | 36 (56.3) | |
M3 | 17 (13.2) | 12 (18.5) | 5 (7.8) | |
M4 | 13 (10.1) | 6 (9.2) | 7 (10.9) | |
M5 | 34 (26.4) | 27 (41.6) | 7 (10.9) | |
Not determined | 2 (1.6) | 1 (1.5) | 1 (1.6) | |
ELN risk stratification (%) | 0.095 | |||
Favorable | 50 (38.8) | 21 (32.3) | 29 (45.3) | |
Intermediate | 44 (34.1) | 20 (30.8) | 24 (37.5) | |
Adverse | 19 (14.7) | 13 (20.0) | 6 (9.4) | |
No data | 16 (12.4) | 11 (16.9) | 5 (7.8) | |
Cytogenetic risk (%) | 0.304 | |||
Favorable | 39 (30.2) | 17 (26.2) | 22 (34.4) | |
Intermediate | 59 (45.7) | 28 (43.1) | 31 (48.4) | |
Adverse | 15 (11.6) | 9 (13.8) | 6 (9.4) | |
No data | 16 (12.4) | 11 (16.9) | 5 (7.8) | |
Karyotypes (%) | 0.023 | |||
t(8;21)/RUNX1-RUNX1T1 | 18 (14.0) | 4 (6.2) | 14 (21.9) | |
inv(16)/CBFβ-MYH11 | 4 (3.1) | 1 (1.5) | 3 (4.7) | |
t(15;17)/PML-RARA | 17 (13.2) | 12 (18.5) | 5 (7.8) | |
11q23/MLL | 7 (5.4) | 6 (9.2) | 1 (1.6) | |
Normal karyotype | 41 (31.8) | 19 (29.2) | 22 (34.4) | |
Complex karyotype | 5 (3.9) | 2 (3.1) | 3 (4.7) | |
Other karyotype | 21 (16.3) | 10 (15.4) | 11 (17.2) | |
No data | 16 (12.4) | 11 (16.9) | 5 (7.8) | |
FLT3 (%) | 0.007 | |||
FLT3-ITD | 16 (12.4) | 14 (21.5) | 2 (3.1) | |
FLT3-TKD | 4 (3.1) | 2 (3.1) | 2 (3.1) | |
Wild | 85 (65.9) | 40 (61.6) | 45 (70.3) | |
No data | 24 (18.6) | 9 (13.8) | 15 (23.4) | |
CEBPA (%) | < 0.001 | |||
Single mutation | 3 (2.3) | 2 (3.1) | 1 (1.6) | |
Double mutation | 15 (11.6) | 1 (1.5) | 14 (21.9) | |
Wild | 87 (67.4) | 53 (81.6) | 34 (53.1) | |
No data | 24 (18.6) | 9 (13.8) | 15 (23.4) | |
DNMT3A (%) | 0.023 | |||
Mutated | 6 (4.7) | 6 (9.2) | 0 (0.0) | |
Wild | 99 (76.7) | 50 (77.0) | 49 (76.6) | |
No data | 24 (18.6) | 9 (13.8) | 15 (23.4) | |
IDH1 (%) | 0.079 | |||
Mutated | 7 (5.4) | 6 (9.2) | 1 (1.6) | |
Wild | 98 (76.0) | 50 (77.0) | 48 (75.0) | |
No data | 24 (18.6) | 9 (13.8) | 15 (23.4) | |
IDH2 (%) | 0.002 | |||
Mutated | 10 (7.8) | 10 (15.4) | 0 (0.0) | |
Wild | 95 (73.6) | 46 (70.8) | 49 (76.6) | |
No data | 24 (18.6) | 9 (13.8) | 15 (23.4) | |
NPM1 (%) | < 0.001 | |||
Mutated | 23 (17.8) | 20 (30.8) | 3 (4.7) | |
Wild | 82 (63.6) | 36 (55.4) | 46 (71.9) | |
No data | 24 (18.6) | 9 (13.8) | 15 (23.4) | |